1. Home
  2. GAIA vs NXTC Comparison

GAIA vs NXTC Comparison

Compare GAIA & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaia Inc.

GAIA

Gaia Inc.

HOLD

Current Price

$1.40

Market Cap

31.8M

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$5.35

Market Cap

30.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAIA
NXTC
Founded
1988
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.8M
30.1M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
GAIA
NXTC
Price
$1.40
$5.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$3.88
★ $20.00
AVG Volume (30 Days)
79.0K
★ 81.1K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.18
N/A
EPS
★ N/A
N/A
Revenue
$4,500,000.00
★ $22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.32
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.50
N/A
52 Week Low
$1.16
$1.55
52 Week High
$6.13
$15.74

Technical Indicators

Market Signals
Indicator
GAIA
NXTC
Relative Strength Index (RSI) 51.90 46.42
Support Level $1.17 $5.60
Resistance Level $1.79 $8.68
Average True Range (ATR) 0.07 0.72
MACD 0.01 0.07
Stochastic Oscillator 76.92 33.71

Price Performance

Historical Comparison
GAIA
NXTC

About GAIA Gaia Inc.

Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: